Monday, February 9, 2026 at 6:19 PM
Eli Lilly has announced its acquisition of Orna Therapeutics for up to $2.4 billion, aiming to enhance its capabilities in genetic medicine and in-vivo cell engineering.
Chinese drugmaker Innovent Biologics and Eli Lilly plan to target cancer and immune system diseases under the partnership.
Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.
Texas Instruments agreed to acquire Silicon Labs in a deal with an enterprise value of about $7.5 billion, including cash and debt.
The deal marks the latest tie-up in the asset-management industry as firms are racing to build the scale needed to weather relentless fee pressure.
Data sourced from public RSS feeds and News APIs.
